natgillin/translations-raw huggingface dataset:
In these studies, (Invented name)® produced a significantly higher rate of response (defined by a 50% decrease in the HAM-D score) and remission, compared to placebo.
V teh študijah je (Izmišljeno ime)® v primerjavi s placebom povzročil značilno višjo stopnja odziva (določeno kot 50 % zmanjšanje števila točk po lestvici HAM-D) in remisije.
Obsessive-compulsive disorder.
Obsesivno-kompulzivna motnja.
Fluoxetine can be used during pregnancy, but caution should be exercised when prescribing to pregnant women, especially during late pregnancy or just prior to the onset of labour since the following effects have been reported in neonates: irritability, tremor, hypotonia, persistent crying, difficulty in sucking or in sleeping.
Fluoksetin med nosečnostjo lahko uporabljamo, vendar je potrebna previdnost pri predpisovanju fluoksetina nosečim ženskam, zlasti v pozni nosečnosti ali tik pred porodom, ker so pri novorojenčkih poročali o naslednjih učinkih: razdražljivost, tresenje, hipotonija, vztrajno jokanje, težave pri sesanju ali motnje spanja.
However caution should be exercised when used during pregnancy, especially during late pregnancy or just before giving birth since the following effects have been reported in new born children: irritability, tremor, muscle weakness, persistent crying, difficulty in sucking or in sleeping.
Kljub temu je ob uporabi med nosečnostjo potrebna previdnost, zlasti v pozni nosečnosti ali tik pred porodom, ker so pri novorojenčkih poročali o naslednjih učinkih: razdražljivost, tresenje, mišična šibkost, vztrajno jokanje, težave pri sesanju ali motnje spanja.
The majority of reports were associated with older patients, and patients taking diuretics or otherwise volume depleted.
V večini primerov je šlo za starejše bolnike in bolnike, ki so jemali diuretike ali bili iz drugih vzrokov hipovolemični.
• have epilepsy or have had a fit in the past; if you have a fit (seizure) or experience an increase in seizure frequency, contact your doctor immediately, the use of fluoxetine might need to be discontinued.
• imate epilepsijo ali ste kdaj imeli epileptični napad; če imate napad (krč) ali se je pogostnost napadov pri vas povečala, se takoj obrnite na svojega zdravnika, morda bo potrebna prekinitev uporabe fluoksetina.
• Take the bottle of (Invented name)® with you if you can.
• Če je mogoče, vzemite s seboj steklenico (Izmišljeno ime)®.
- NIMH Prospective placebo-controlled study: The MAHs committed to assess the possibilities to include the evaluation of the effect of fluoxetine on sexual maturation in children aged 8 - 12
- Prospektivna, s placebom primerjana raziskava Nacionalnega inštituta za mentalno zdravje: Imetnik dovoljenja za promet z zdravilom je prevzel obveznost, da bo preučil možnosti za vključitev vrednotenja učinka fluoksetina na spolno dozorevanje pri otrocih, starih od 8 do 12
INFORMATION IN BRAILLE (Invented name)® 20 mg
PODATKI V BRAILLOVI PISAVI (Izmišljeno ime)® 20 mg
• Obsessive-compulsive disorder
• obsesivno-kompulzivno motnje
• phenytoin (for epilepsy); because (Invented name)® may influence the blood levels of this drug, your doctor may need to introduce phenytoin more carefully and carry out check-ups when given with (Invented name)®.
• fenitoin (za epilepsijo); ker (Izmišljeno ime)® lahko vpliva na vrednosti tega zdravila v krvi, bo ob jemanju (Izmišljeno ime)® vaš zdravnik morda previdneje uvedel fenitoin in vas naročil na redne preglede.
If you forget to take (Invented name)®
Če ste pozabili vzeti zdravilo (Izmišljeno ime)®
Hallucinations, manic reaction, confusion, agitation, anxiety and associated symptoms (e.g. nervousness), impaired concentration and thought process (e.g. depersonalisation), panic attacks, suicidal thoughts and behaviour (these symptoms may be due to the underlying disease), very rarely serotonin syndrome.
Halucinacije, manična reakcija, zmedenost, vznemirjenost, anksioznost in z njimi povezani simptomi (npr. živčnost), motnje zbranosti in miselnega procesa (npr. depersonalizacija), panični napadi, samomorilne misli in vedenje (ti simptomi se lahko pojavijo zaradi osnovne bolezni), zelo redko serotoninski sindrom.
• If you take too many capsules, go to your nearest hospital emergency department (or casualty)
• Če zaužijete preveč kapsul, pojdite na urgentni oddelek najbližje bolnišnice ali takoj sporočite svojemu zdravniku.
Concomitant therapy with drugs predominantly metabolised by this isoenzyme, and which have a narrow therapeutic index (such as flecainide, encainide, carbamazepine and tricyclic antidepressants), should be initiated at or adjusted to the low end of their dose range.
Sočasno zdravljenje z zdravili, ki se presnavljajo predvsem s tem izoencimom in imajo ozek terapevtski indeks (kot so flekainid, enkainid, karbamazepin in triciklični antidepresivi), je treba začeti z nižjimi vrednostmi razpona njihovega odmerjanja ali pa jih takšnim vrednostim prilagoditi.
Maximum recommended dose is 60 mg/day.
Najvišji priporočeni odmerek je 60 mg/dan.
As these syndromes may result in potentially life-threatening conditions, treatment with fluoxetine should be discontinued if such events (characterised by clusters of symptoms such as hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, mental status changes including confusion, irritability, extreme agitation progressing to delirium and coma) occur and supportive symptomatic treatment should be initiated.
Ker ti sindromi lahko povzročijo potencialno življenjsko nevarna stanja, moramo zdravljenje s fluoksetinom ob pojavu takih dogodkov (ki jih označujejo skupki simptomov, kot so hipertermija, rigidnost, mioklonus, avtonomna labilnost z možnimi hitrimi nihanji vitalnih znakov, spremembe mentalnega stanja, vključujoč zmedenost, razdražljivost, skrajno vznemirjenost, ki napredujejo v delirij in komo) prekiniti in uvesti podporno simptomatsko zdravljenje.
Caution is advised in patients taking SSRI's, particularly in concomitant use with oral anticoagulants, drugs known to affect platelet function (e.g. atypical antipsychotics such as clozapine, phenothiazines, most TCA's, aspirin, NSAID's) or other drugs that may increase risk of bleeding as well as in patients with a history of bleeding disorders.
Pri bolnikih, ki jemljejo selektivne zaviralce prevzema serotonina je potrebna previdnost, zlasti ob sočasni uporabi peroralnih antikoagulantov, zdravil, za katere vemo, da vplivajo na delovanje trombocitov (npr. atipični antipsihotiki, kot so klozapin, fenotiazini, večina tricikličnih antidepresivov, aspirin, nesteroidna protivnetna zdravila), ali drugih zdravil, ki lahko povečajo tveganje za krvavitev, kot tudi pri bolnikih, ki imajo v anamnezi motnje strjevanja krvi.
• Bulimia nervosa: The recommended dose is 60 mg daily.
• bulimija nervoza: Priporočeni odmerek je 60 mg na dan.
Suicide-related behaviours (suicide attempt and suicidal thoughts), and hostility (predominantly aggression, oppositional behaviour and anger) were more frequently observed in clinical trials among children and adolescents treated with antidepressants compared to those treated with placebo.
S samomorom povezana vedenja, (poskus samomora in samomorilne misli) ter sovražnost (večinoma nasilno vedenje, nasprotovalno vedenje in jeza) so bila v kliničnih preskušanjih pogosteje opažena pri otrocih in mladostnikih, ki so bili zdravljeni z antidepresivnimi zdravili, v primerjavi s tistimi, ki so prejemali placebo.
Cases of overdose of fluoxetine alone usually have a mild course.
Primeri prevelikega odmerjanja fluoksetina samega običajno potekajo blago.
Dosage should be reviewed and adjusted if necessary within 3 to 4 weeks of initiation of therapy and thereafter as judged clinically appropriate.
V 3 do 4 tednih po začetku zdravljenja ter kasneje je treba oceniti odmerjanje in ga v skladu s klinično presojo po potrebi prilagoditi.
If you stop taking (Invented name)®
Če ste prenehali jemati zdravilo (Izmišljeno ime)®
• Bulimia nervosa: (Invented name)® is used alongside psychotherapy for the reduction of binge eating and purging
• bulimije nervoze: (Izmišljeno ime)® uporabljamo v kombinaciji s psihoterapijo za zmanjševanje epizod prenajedanja in bruhanja
Hypersensitivity to fluoxetine or to any of the excipients.
Preobčutljivost za fluoksetin ali katerokoli pomožno snov.
Due to higher plasma levels in lower weight children, the therapeutic effect may be achieved with lower doses (see Section 5.2 Pharmacokinetic properties).
Pri otrocih z manjšo telesno maso lahko glede na višje vrednosti koncentracije zdravila v plazmi dosežemo terapevtski učinek že pri nižjih odmerkih (glejte poglavje 5.2 Farmakokinetične lastnosti).
If (Invented name)® has been prescribed for a long period and/or at a high dose, a longer interval needs to be considered by your doctor.
Če so vam (Izmišljeno ime)® predpisali za dolgo obdobje in/ali v visokem odmerku, naj vaš zdravnik premisli o daljšem intervalu od prenehanja jemanja MAOI.
Pharmaceutical grade edible printing ink components: Formulation 1:
Sestavine farmacevtskega užitnega tiskalnega črnila:
Only after one to two weeks, the dose may be increased to 20mg/day.
Šele po enem do dveh tednih se odmerek lahko poveča na 20 mg/dan.
However, the CHMP requested the MAH to undertake an additional study in young rats, to assess the neurohormonal status of hypothalamic-pituitary-gonadal (HPG) axis during sexual maturation of juvenile male and female rats.
Vendarle pa je CHMP od imetnika dovoljenja za promet z zdravilom zahteval, da izvede dodatno raziskavo pri mladih podganah za ocenitev nevrohormonskega statusa osi hipotalamus-hipofiza-spolne žleze (HPG) med spolnim dozorevanjem mladih podgan moškega in ženskega spola.
At 10 mg/kg/day, plasma levels achieved in animals were approximately 0.8 to 8.8 fold (fluoxetine) and 3.6 to 23.2 fold (norfluoxetine) those usually observed in paediatric patients.
Pri odmerku 10 mg/kg/dan so plazemske vrednosti pri živalih dosegle približno 0,8 do 8,8 krat (fluoksetin) oziroma 3,6 do 23,2 krat (norfluoksetin) višje vrednosti v primerjavi z vrednostmi, ki jih navadno opažamo pri pediatričnih bolnikih.
Fluoxetine is secreted into breast milk.
Fluoksetin se izloča v materino mleko.
Dizziness, sensory disturbances (including paraesthesia), sleep disturbances (including insomnia and intense dreams), asthenia, agitation or anxiety, nausea and/or vomiting, tremor and headache are the most commonly reported reactions.
Omotica, senzorične motnje (vključno s parestezijami), motnje spanja (vključno z nespečnostjo in intenzivnimi sanjami), astenija, agitacija ali tesnobnost, slabost in/ali bruhanje, tresenje in glavobol so reakcije, o katerih bolniki najpogosteje poročajo.
The black edible printing ink consists of shellac, propylene glycol, ammonium hydroxide, black iron oxide (E172) (formulation 1) or shellac, soya lecithin, antifoam DC 1510, black iron oxide (E172) (formulation 2).
Užitno tiskalno črnilo je iz šelaka, propilenglikola, amonijevega hidroksida, črnega železovega oksida (E172) (formulacija 1) ali šelaka, lecitina soje, sredstva proti penjenju DC 1510 in črnega železovega oksida (E172) (formulacija 2).
Urogenital system and reproductive disorders - difficulty passing urine or passing urine too frequently, poor sexual performance, prolonged erections, and producing breastmilk.
Sečila, spolovila in motnje reprodukcije - težave pri uriniranju ali pogosto uriniranje, spolna neučinkovitost, podaljšana erekcija in izločanje materinega mleka.
Major depressive episodes.
Velike depresivne epizode.
Serotonergic drugs: Co-administration with serotonergic drugs (e.g. tramadol, triptans) may increase the risk of serotonin syndrome.
Serotoninergična zdravila: Sočasno jemanje serotoninergičnih zdravil (npr, tramadola, triptanov) lahko poveča tveganje za serotoninski sindrom.
(Invented name)® should only be used in children and adolescents aged 8 to 18 years for the treatment of moderate to severe major depressive episodes (in combination with psychological therapy) and it should not be used in other indications.
(Izmišljeno ime)® uporabljamo pri otrocih in mladostnikih, starih 8 do 18 let, za zdravljenje zmernih do hudih velikih depresivnih epizod (v kombinaciji s psihološko terapijo) in ga za druge indikacije ne uporabljamo.
Hyponatraemia: Hyponatraemia (including serum sodium below 110 mmol/l) has been rarely reported and appeared to be reversible when fluoxetine was discontinued.
Hiponatremija: Redko so poročali o hiponatremiji (vključujoč serumsko koncentracijo natrija pod 110 mmol/l), ki se je popravila po prekinitvi zdravljenja s fluoksetinom.
The starting dose was agreed to be 10mg/day given as 2.5ml of the Prozac liquid formulation.
Dogovorjeno je bilo, da bo začetni odmerek znašal 10 mg/dan, ki so ga dajali v obliki 2,5 ml tekočega pripravka Prozaca.
Examples of MAOIs include nialamide, iproniazide, selegeline, moclobemide, phenelzine, tranylcypromine, isocarboxazid and toloxatone.
Med MAOI sodijo nialamid, iproniazid, selegelin, moklobemid, fenelzin, tranilcipromin in izokarboksazid in toloksaton.
Electroconvulsive Therapy (ECT): There have been rare reports of prolonged seizures in patients on fluoxetine receiving ECT treatment, therefore caution is advisable.
Elektrokonvulzivna terapija (EKT): Pri bolnikih, ki so prejemali fluoksetin in zdravljenje z EKT, so redko poročali o podaljšanih krčih, zato je potrebna previdnost.
Adults and the elderly: The recommended dose is 20mg daily.
Odrasli in starejši: Priporočeni odmerek je 20 mg na dan.
Obsessive-compulsive disorder
Obsesivno-kompulzivna motnja
The maximum dose is 60 mg per day.
Najvišji priporočeni odmerek je 60 mg na dan
Cardiac Disease: No conduction abnormalities that resulted in heart block were observed in the ECG of 312 patients who received fluoxetine in double blind clinical trials.
Srčna obolenja: V elektrokardiogramih 312 bolnikov, ki so prejemali fluoksetin v dvojno slepih kliničnih preskušanjih, niso opažali nobenih motenj prevajanja, ki bi imele za posledico srčni blok.
INFORMATION IN BRAILLE (Invented name)® 20 mg per 5 ml
PODATKI V BRAILLOVI PISAVI (Izmišljeno ime)® 20 mg na 5 ml
- Juvenile rat study to characterize the development and potential reversibility of testicular toxicity (ie, neurohormonal and histopathologic evaluations) in male juvenile CD rats administered fluoxetine.
- Raziskavo pri mladih podganah za ugotavljanje razvoja in morebitne reverzibilnosti škodljivega delovanja na moda (tj. nevrohormonska in histopatološka vrednotenja) pri mladih CD podganah moškega spola, ki so prejemale fluoksetin.
Nervous system - headache, sleep problems or unusual dreams, dizziness, poor appetite, tiredness, abnormally high mood, uncontrollable movements, fits, extreme restlessness, hallucinations, untypical wild behaviour, confusion, agitation, anxiety, nervousness, not being able to concentrate or think properly, panic attacks; or thoughts of suicide or harming yourself.
Živčevje - glavobol, težave s spanjem ali nenavadne sanje, vrtoglavost, zmanjšanje apetita, utrujenost, nenormalno dobro razpoloženje, nehotni gibi, krči, hud nemir, halucinacije, netipično divje vedenje, zmedenost, vznemirjenost, anksioznost, razdražljivost, nezmožnost koncentracije ali razsodnega razmišljanja, napadi panike; ali misli na samomor ali samopoškodbo.
Therefore, fluoxetine is contra-indicated in combination with a non-selective MAOI.
Fluoksetin je torej v kombinaciji z neselektivnimi zaviralcem monoaminooksidaze kontraindiciran.
It is therefore advised that when (Invented name)® treatment is no longer required, gradual discontinuation by dose tapering should be carried out (see section 4.2 Posology and Method of Administration and section 4.4 Special warnings and precautions for use).
Zato svetujemo, da ko zdravljenje s (Izmišljeno ime)® ni več potrebno, ga postopno prekinemo z zmanjševanjem odmerka (glejte poglavje 4.2 Odmerjanje in način uporabe in poglavje 4.4 Posebna opozorila in previdnostni ukrepi).
The combination of fluoxetine with a reversible MAOI (e.g. moclobemide) is not recommended.
Kombinacijo fluoksetina z reverzibilnim zaviralcem monoaminooksidaze (npr. moklobemidom) odsvetujemo.
Preclinical safety data
5.3 Predklinični podatki o varnosti
For oral administration.
Samo za peroralno jemanje.
Lithium and tryptophan: There have been reports of serotonin syndrome when SSRIs have been given with lithium or tryptophan and, therefore, the concomitant use of fluoxetine with these drugs should be undertaken with caution.
Litij in triptofan: Ob sočasnem dajanju selektivnih zaviralcev prevzema serotonina z litijem ali triptofanom so poročali o serotoninskem sindromu, zato je pri sočasni uporabi fluoksetina s temi zdravili potrebna previdnost.
(Invented name)® is one of a group of medicines called selective serotonin re-uptake inhibitor (SSRI) antidepressants.
KAJ JE (IZMIŠLJENO IME)® IN ZA KAJ GA UPORABLJAMO (Izmišljeno ime)® je eno od antidepresivnih zdravil, imenovanih selektivni zaviralci prevzema serotonina (SSRI).
Growth and pubertal development (height, weight and TANNER staging) should therefore be monitored during and after treatment with fluoxetine.
Zato moramo med in po končanem zdravljenju s fluoksetinom nadzorovati rast in pubertetni razvoj (telesno višino, maso in stopnjo zrelosti po TANNER-ju).
Therefore, as with other antidepressants, fluoxetine should be introduced cautiously in patients who have a history of seizures.
Zato je treba podobno kot pri drugih antidepresivih fluoksetin pri tistih bolnikih, ki so že imeli krče, uvajati postopno.
Monoamine Oxidase Inhibitors: Cases of serious and sometimes fatal reactions have been reported in patients receiving an SSRI in combination with a monoamine oxidase inhibitor (MAOI), and in patients who have recently discontinued an SSRI and have been started on a MAOI.
Zaviralci monoaminooksidaze: Poročali so o resnih in včasih usodnih reakcijah pri bolnikih, ki so prejemali selektivni zaviralec prevzema serotonina v kombinaciji z zaviralcem monoaminooksidaze, ter pri bolnikih, ki so nedavno prekinili zdravljenje s selektivnim zaviralcem prevzema serotonina in začeli zdravljenje z zaviralcem monoaminooksidaze.
Abnormal liver function tests have been reported rarely.
Redko so poročali o nenormalnih vrednostih testov jetrnega delovanja.
Weight Loss: Weight loss may occur in patients taking Fluoxetine but it is usually proportional to baseline body weight.
Znižanje telesne mase: Pri bolnikih, ki jemljejo fluoksetin, se lahko telesna masa zniža, vendar je to navadno sorazmerno z izhodiščno telesno maso.
• Depression: The recommended dose is 20 mg daily.
• depresija: Priporočeni odmerek je 20 mg na dan.
The MAH should perform the following studies and report the results to the RMS:
Imetnik dovoljenja za promet z zdravilom mora opraviti naslednje raziskave in rezultate sporočiti referenčni državi članici:
Eli Lilly and Co Ltd, Kingsclere road, Basingstoke, Hampshire RG21 6XA, ENGLAND
Velika Britanija Eli Lilly and Co Ltd, Kingsclere Road, Basingstoke, Hampshire RG21 6XA, VELIKA BRITANIJA
PHARMACEUTICAL FORM AND CONTENTS <[See Annex I - To be completed nationally]>
FARMACEVTSKA OBLIKA IN VSEBINA <[Glejte Dodatek I - Dopolnjeno nacionalno]>
You may notice the following effects when you stop taking (Invented name)®: dizziness; tingling feelings like pins and needles; sleep disturbances (vivid dreams, nightmares, inability to sleep); feeling restless or agitated; unusual tiredness or weakness; feeling anxious; nausea/vomiting (feeling sick or being sick); tremor (shakiness); headaches.
Ko prenehate jemati (Izmišljeno ime)®, lahko opazite naslednje učinke: omotico; zbadajoče občutke v obliki mravljincev; motnje spanja (živahne sanje, nočne more, nezmožnost spanja); občutek nemira ali vznemirjenosti; nenavadno utrujenost ali šibkost; občutek tesnobnosti; slabost/bruhanje (slabo počutje); tresenje; glavobole.
Fluoxetine is well absorbed from the gastrointestinal tract after oral administration.
Fluoksetin se po peroralnem jemanju iz prebavil dobro absorbira.
PARTICULARS TO APPEAR ON THE BOTTLE CARTONS FOR PROZAC 20 mg per 5 ml oral liquid
PODATKI NA STEKLENICI ŠKATLE ZA PROZAC 20 mg na 5 ml PERORALNE RAZTOPINE
Major depressive episodes
Velike depresivne epizode
The MAH suggested the involvement of fluoxetine-induced inhibition of GnRH, so that fluoxetine would act as an endocrine disrupter.
Imetnik dovoljenja za promet z zdravilom je podal domnevo, da gre za vpletenost s fluoksetinom povzročenega zaviranja GnRH, tako da bi fluoksetin deloval kot uničevalec žlez z notranjim izločanjem.
Other - hair loss, yawning, blurred vision, unexplained bruising or bleeding, sweating, hot flushes, feeling dizzy when you stand up, or joint or muscle pain, low levels of sodium in the blood.
Drugo - izpadanje las, zehanje, zamegljen vid, nerazložljive podplutbe ali krvavitve, znojenje, navali vročine, občutek vrtoglavice ob vstajanju ali bolečine v mišicah ali sklepih, nizke vrednosti natrija v krvi.
At 3 mg/kg/day, plasma levels achieved in animals were approximately 0.04 to 0.5 fold (fluoxetine) and 0.3 to 2.1 fold (norfluoxetine) those usually achieved in paediatric patients.
Pri odmerku 3 mg/kg/dan so plazemske vrednosti pri živalih dosegle približno 0,04 do 0,5 krat (fluoksetin) oziroma 0,3 do 2,1 krat (norfluoksetin) višje vrednosti v primerjavi z vrednostmi, ki jih navadno opažamo pri pediatričnih bolnikih.
However treatment with fluoxetine can be started the following day after discontinuation of certain MAOIs called reversible MAOI-A (for instance moclobemide)
Zdravljenje s fluoksetinom lahko začnete naslednji dan po prekinitvi zdravljenja z nekaterimi MAOI, tako imenovanimi reverzibilnimi MAOI-A (na primer, moklobemid).
The starting dose is 10mg/day (given as 2.5ml of (Invented name)® oral liquid).
Začetni odmerek je 10 mg/dan (ki ga damo kot 2,5 ml (Izmišljeno ime)® peroralne raztopine).
Hypoglycaemia has occurred during therapy with fluoxetine and hyperglycaemia has developed following discontinuation.
Med zdravljenjem s fluoksetinom se je pojavljala hipoglikemija, po prekinitvi fluoksetina pa se je razvila hiperglikemija.
It is therefore advised that (Invented name)® should be gradually tapered when discontinuing treatment over a period of at least one to two weeks, according to the patient's needs (see "Withdrawal Symptoms Seen on Discontinuation of (Invented name)®", Section 4.2 Posology and Method of Administration).
Zato svetujemo, da (Izmišljeno ime)® ob prekinitvi zdravljenja postopno zmanjšujemo v obdobju najmanj enega do dveh tednov, glede na bolnikove potrebe (glejte Odtegnitveni simptomi ob prekinitvi zdravljenja s (Izmišljeno ime)®, poglavje 4.2 Odmerjanje in način uporabe).
Respiratory System - sore throat, shortness of breath.
Dihala - vneto žrelo, kratka sapa.
- Juvenile rat study to evaluate neurohormonal status of hypothalamic-pituitary-gonadal (HPG) axis during sexual maturation of juvenile CD male and female rats administered fluoxetine.
- Raziskavo pri mladih podganah za vrednotenje nevrohormonskega statusa osi hipotalamushipofiza-spolne žleze (HPG) med spolnim dozorevanjem mladih CD podgan moškega in ženskega spola, ki so prejemale fluoksetin.
Symptoms of a drug interaction with a MAOI include: hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, mental status changes that include confusion, irritability and extreme agitation progressing to delirium and coma.
Simptomi medsebojnega delovanja z zaviralcem monoaminooksidaze vključujejo: hipertermijo, rigidnost, mioklonus, avtonomno labilnost z možnimi hitrimi nihanji vitalnih znakov, spremembe v mentalnem stanju, ki vključujejo zmedenost, razdražljivost in skrajno vznemirjenost ter se razvijejo v delirij in komo.
• a combination of symptoms (know as serotonin syndrome) including unexplained fever with faster breathing or heart rate, sweating, muscle stiffness or tremor, confusion, extreme agitation or sleepiness (only rarely);
kombinacijo simptomov (znano kot serotoninski sindrom) z nerazložljivim povišanjem telesne temperature, pospešenim dihanjem ali bitjem srca, znojenjem, odrevenelimi mišicami ali tresenjem, zmedenostjo, hudo vznemirjenostjo ali zaspanostjo (le redko),